USP2 and hepatocellular carcinoma: Importantly, compared with control groups, the tumors’ weight and volume were the smallest in the group treated with lenvatinib and USP2-AS1 knockdown (Figures 6D, E), indicating that USP2-AS1 knockdown can enhance the therapeutic effect of lenvatinib in HCC in our mice tumor xenograft model.